Skip to main content

Table 4 Common adverse events of sequential TKI treatment

From: Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

Adverse events related to first-line treatment with sunitinib Any grade (%) Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%) **
Any adverse event* 129 (97) 20 (15) 57 (43) 51 (38) 1 (1)
Thrombocytopenia 39 (30) 8 (6) 13 (10) 17 (13) 1 (1)
Neutropenia 16 (12) 7 (5) 3 (2) 6 (5)  
HFSR** 104 (79) 53 (40) 37 (28) 14 (11)  
Mucositis 109 (83) 43 (33) 42 (32) 24 (18)  
Diarrhea 89 (67) 51 (39) 26 (20) 12 (8)  
Nausea 25 (19) 20 (15) 5 (4) 0 (0)  
Fatigue 79 (60) 51 (39) 22 (17) 6 (4)  
High blood pressure 37 (28) 23 (17) 10 (8) 4 (3) 0 (0)
Adverse events related to second-line treatment with sorafenib
 Any adverse event 123 (93) 22 (17) 25 (49) 37 (28) 1 (1)
 Hypothyroidism 38 (29) 25 (18) 12 (9) 1 (1)
 HFSR 105 (80) 56 (42) 30 (23) 19 (14)  
 Rash 26 (20) 19 (14) 5 (4) 2 (2)  
 Mucositis 70 (53) 44 (33) 20 (15) 6 (5)  
 Diarrhea 100 (76) 51 (39) 43 (33) 6 (4)  
 Nausea 44 (34) 38 (29) 5 (4) 1 (1)  
 Fatigue 106 (80) 62 (47) 35 (27) 9 (7)  
 High blood pressure 12 (9) 4 (3) 7 (5) 0 (0) 1 (1)
  1. *Any adverse event for patient, graded as maximum; **HFSR Hand-foot skin reaction; **Grade 4 only in those cases classified according to toxicity grades by the common Terminology Criteria for Adverse Events (CTCAE) classification [20]
\